Epidemiology


Etiology

  • Types by location:
    • Membranous (perimembranous): ~80%, most common
    • Muscular (trabecular): may close spontaneously
    • Inlet (AV canal type): assoc. w/ Down syndrome
    • Outlet (subarterial/supracristal)

Pathophysiology


Clinical features

  • Small VSD (Restrictive): Usually asymptomatic.
    • Loud, harsh holosystolic murmur at left lower sternal border (LLSB).
    • Palpable thrill may be present.
  • Large VSD (Unrestrictive): Presents at 4-6 weeks of life as pulmonary vascular resistance (PVR) drops. So it may not be heard at birth
    • Heart failure (HF) symptoms: Failure to thrive (FTT), tachypnea, diaphoresis w/ feeding, hepatomegaly.
    • Softer holosystolic murmur (less turbulence).
    • Apical diastolic rumble (due to relative mitral stenosis from ↑ pulmonary venous return to LA/LV).
    • Prominent P2 (if pulmonary HTN develops).

Diagnostics

  • Initial: ECG and CXR.
    • ECG: Small VSD = normal. Large VSD = LA & LV hypertrophy (volume overload); RVH if pulmonary HTN develops.
    • CXR: Small VSD = normal. Large VSD = Cardiomegaly, ↑ pulmonary vascular markings.
  • Confirmatory/Gold Standard: Echocardiography (visualizes defect size, location, and shunt gradient/direction).
  • Cardiac Catheterization: Rarely needed for diagnosis; used to assess pulmonary artery pressures if Eisenmenger syndrome is suspected.

Treatment

  1. Small/Asymptomatic: Observation. ~75% close spontaneously by age 1-2 years. Routine IE prophylaxis not indicated. c
    • Mechanism: As the infant grows, the existing cardiomyocytes undergo hypertrophy (increase in size, not number).
  2. Large/Symptomatic (Medical Management): Used as a bridge to surgery.
    • HF control: Diuretics (furosemide), ACEi (reduces afterload, promoting systemic flow over shunt), digoxin.
    • Nutrition: High-calorie fortified feeds/NG tube for FTT.
  3. Definitive (Surgical Closure):
    • Indications: Refractory HF, FTT, or development of pulmonary HTN.
    • Timing: Usually repaired at 3-6 months of age to prevent irreversible pulmonary vascular disease.